Pharmaceutical companies with the most orphan drugs

The US FDA grants drugs addressing rare ‘orphan diseases’ strong exclusivity protection for seven years, barring any other approval for a similar drug treating the same disease. The article continues to provide a chart showing companies that have received the most orphan drug exclusivities in the past five years.